从吉利德研发核心大咖到柯君医药创始人：何公欣博士与AI+前药技术的全球突破

Core Insights - The article highlights the emergence of prodrug technology as a pivotal strategy in drug development, showcasing its ability to enhance drug delivery and efficacy through chemical modifications that allow drugs to bypass biological barriers and release at targeted sites [1][19]. Group 1: Prodrug Technology Development - Prodrug technology has evolved from a tool for optimizing pharmacokinetics to a core strategy in drug development, with significant advancements in the last sixty years [19]. - The development of prodrugs has gone through several stages, including simple esterification, guided structural prodrugs, and microenvironment-triggered prodrugs, each enhancing the precision and effectiveness of drug delivery [13][14][15]. Group 2: Dr. He Gongxin's Contributions - Dr. He Gongxin has played a crucial role in the development of prodrug technology, having worked at Gilead for nearly 30 years and contributing to the creation of several internationally recognized prodrugs, including tenofovir alafenamide (TAF) [3][5]. - After establishing a strong foundation in synthetic and medicinal chemistry, Dr. He founded Kejun Pharmaceutical in Shanghai in 2018, focusing on the next generation of prodrug technology using AI and spatial chemistry [6][8]. Group 3: Kejun Pharmaceutical's Innovations - Kejun Pharmaceutical has developed several innovative drugs with global market potential based on its A-ProX AI prodrug technology platform, including CG-0255 and CG-0416, which show promise as Best-in-Class therapies [8][10]. - CG-0255, a novel P2Y12 receptor antagonist, overcomes limitations of traditional antiplatelet drugs by utilizing a hydrolyzed prodrug design, leading to rapid onset of action and improved safety profiles [9][10]. - CG-0416 targets metabolic-associated fatty liver disease (MASH) and demonstrates significant efficacy in reducing liver fat accumulation and inflammation, with promising clinical data supporting its use in combination therapies [10][11]. Group 4: Future Prospects - The integration of AI and spatial chemistry in prodrug design is expected to propel the industry into a new era of intelligent, precise, and personalized medicine, addressing unmet clinical needs and enhancing drug development efficiency [15][19]. - As prodrug technology continues to advance, it is anticipated to provide innovative solutions across various disease areas, completing the value chain from molecular modification to patient benefit [19].